Loading
FDA018-ADC is an experimental antibody-drug conjugate from Shanghai Fudan-Zhangjiang Bio-Pharmaceutical in phase 3 trials for triple-negative breast cancer, with its target not yet stated publicly.
FDA018-ADC (FDA018) is an antibody-drug conjugate developed by Shanghai Fudan-Zhangjiang Bio-Pharmaceutical. Its molecular target is not stated in the ClinicalTrials.gov intervention record, and OnCo has not confirmed one from the sponsor's pipeline page. ClinicalTrials.gov describes the intervention as: Subjects will receive FDA018-ADC 10 mg/kg of body weight via intravenous(IV) infusion on Day1 and 8 of a 21-day cycle in follow-up period until disease progression, unacceptable toxicity or death. It is the investigational product in 1 recruiting or active industry-led phase 2 and phase 3 interventional cancer trial, including the phase 3 study NCT06519370 (FDA018-ADC vs Investigator's Choice Chemotherapy to Treat Locally Advanced, Recurrent or Metastatic Triple-negative Breast Cancer), in triple-negative breast cancer. The largest, NCT06519370, plans to enrol 350 participants with primary completion was scheduled for 2026-08-18 on the registry. Status reflects the highest phase registered on ClinicalTrials.gov; no efficacy results are recorded here.
Mechanism not stated in the ClinicalTrials.gov record or on the sponsor's pipeline page.
1.FDA018-ADC's antibody arm binds its target on the surface of the cancer cell.
Background: ADC sequencing, Antigen escape (antigen loss, lineage switch), BCG-unresponsive, Castration-resistant prostate cancer (CRPC), Circulating tumour DNA (ctDNA). Also on OnCo: Resistance: how tumours escape each drug class · Lines of therapy.
Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.
Query for this drug: (TITLE:"FDA018-ADC" OR ABSTRACT:"FDA018-ADC" OR TITLE:"FDA018" OR ABSTRACT:"FDA018" OR TITLE:"FDA018-Antibody-drug Conjugate" OR ABSTRACT:"FDA018-Antibody-drug Conjugate") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about FDA018-ADC, not a curated reading list.
Shares Triple-negative breast cancer (TNBC) and the tag pipeline.
Shares Triple-negative breast cancer (TNBC) and the tag pipeline.
Shares Triple-negative breast cancer (TNBC) and the tag pipeline.
Shares Triple-negative breast cancer (TNBC) and the tag pipeline.
Shares Triple-negative breast cancer (TNBC) and the tag pipeline.
Shares Triple-negative breast cancer (TNBC) and the tag pipeline.
Shares Triple-negative breast cancer (TNBC) and the tag pipeline.
Shares Triple-negative breast cancer (TNBC) and the tag pipeline.